HCA-7 Colony 29

02091238

• Code UNSPSC : 41106514

Propriétés

• Source biologique: human colon
• Mode de croissance: Adherent
• Caryotype: Near Diploid
• Morphologie: Epithelial
• Produits: Expresses Cox-2
• Récepteurs: EGF. Parent HCA-7 cell line: wildtype APC. Known mutations:Parent HCA-7 cell line: RER phenotype, p53
• Technique(s): cell culture | mammalian: suitable
• Maladie(s) pertinente(s): cancer
• Conditions d'expédition: dry ice
• Température de stockage: −196°C

Description

Origine de la lignée cellulaire

Human Colon Carcinoma (subpopulation isolated from the HCA-7 cell line)

Description de la lignée cellulaire

The human colon cancer cell line, HCA-7 Colony 29 expresses Cox-2. An interesting feature of this cell line is that it forms polarised epithelial sheets which allows examination of the trafficking and release of biomolecules in vitro. Cyclooxygenases (COXs) are key enzymes in the conversion of arachidonic acid to prostaglandins and other eicosanoids. It has been found that colonic polyps and cancers overexpress Cox-2 and that the inhibition of this enzyme by nonsteroidal anti-inflammatory drugs decreases the risk of colonic neoplasia. This cell line is useful for studying the role of Cox-2 in cancer cell biology and the investigation of colorectal epithelial cell polarity. Imperial College Innovations has stated that this cell line is not to be supplied to commercial organisations.

Profil d'ADN

STR-PCR Data: Amelogenin: X
CSF1PO: 11,14
D13S317: 9
D16S539: 10,11
D5S818: 8,12
D7S820: 11,12
THO1: 6,7
TPOX: 8,10
vWA: 14,16

Milieu de culture

DMEM + 10% FBS + 2mM L-Glutamine + 110mg/L Sodium Pyruvate (NaP).

Procédure de repiquage

Split sub-confluent cultures (70-80%) 1:5 to 1:10 i.e. seeding at 1-2x10,000 cells/cm² using 0.05% trypsin/EDTA; 5% CO₂; 37°C.

Autres remarques

Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.

Clause de non-responsabilité

This cell line has special release conditions: Commercial organisations are required to complete the ′Cell Line Release Authorisation for Research Use in Commercial Organisations′ release conditions form.